<?xml version="1.0" encoding="UTF-8"?>
<p id="para340">Evidence on the cost of pharmaceutical research and development has been made available since at least the 1950s;
 <xref rid="bib19" ref-type="bibr">
  <sup>19</sup>
 </xref> however, this has been limited to mainly chemical drug products.
 <xref rid="bib20" ref-type="bibr">
  <sup>20</sup>
 </xref> Whereas the Di Masi and colleagues publications
 <xref rid="bib17" ref-type="bibr">17</xref>, 
 <xref rid="bib21" ref-type="bibr">21</xref>, 
 <xref rid="bib22" ref-type="bibr">22</xref>, 
 <xref rid="bib23" ref-type="bibr">23</xref> have provided the foundations on which numerous analyses or critiques of pharmaceutical research and development costs have since been conducted,
 <xref rid="bib16" ref-type="bibr">16</xref>, 
 <xref rid="bib19" ref-type="bibr">19</xref>, 
 <xref rid="bib20" ref-type="bibr">20</xref>, 
 <xref rid="bib24" ref-type="bibr">24</xref>, 
 <xref rid="bib25" ref-type="bibr">25</xref>, 
 <xref rid="bib26" ref-type="bibr">26</xref>, 
 <xref rid="bib27" ref-type="bibr">27</xref>, 
 <xref rid="bib28" ref-type="bibr">28</xref>, 
 <xref rid="bib29" ref-type="bibr">29</xref>, 
 <xref rid="bib30" ref-type="bibr">30</xref>, 
 <xref rid="bib31" ref-type="bibr">31</xref>, 
 <xref rid="bib32" ref-type="bibr">32</xref>, 
 <xref rid="bib33" ref-type="bibr">33</xref> evidence on vaccine-specific research and development costs for epidemic infectious diseases has been scarce for several reasons. First, the process of vaccine development might differ substantially from that of drug development, with implications for scale and intensity of resource use and associated costs by research and development phase.
 <xref rid="bib34" ref-type="bibr">
  <sup>34</sup>
 </xref> Second, the complexity of the platform technologies used to develop vaccines might influence research and development costs.
 <xref rid="bib3" ref-type="bibr">3</xref>, 
 <xref rid="bib20" ref-type="bibr">20</xref>, 
 <xref rid="bib35" ref-type="bibr">35</xref>, 
 <xref rid="bib36" ref-type="bibr">36</xref> The literature assumes that new technologies with no licensure track-record will induce higher research and development costs than well-established technologies. Third, the complexity of the pathogen against which vaccines are developed might affect research and development costs,
 <xref rid="bib3" ref-type="bibr">3</xref>, 
 <xref rid="bib20" ref-type="bibr">20</xref>, 
 <xref rid="bib35" ref-type="bibr">35</xref>, 
 <xref rid="bib36" ref-type="bibr">36</xref> with vaccines against pathogens for which licensed vaccines already exist assumed to cost less.
</p>
